

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

LISTING OF CLAIMS:

1-24. (Canceled).

25. (New): A composition comprising epigallocatechin gallate (EGCG) and phytanic acid, which composition is formulated to treat type 2 diabetes.

26. (New): A nutraceutical composition for treating type 2 diabetes comprising a carrier, epigallocatechin gallate (EGCG), and phytanic acid.

27. (New): A composition comprising epigallocatechin gallate (EGCG) and phytanic acid, which composition is formulated to reduce the incidence or risk of type 2 diabetes in a human at risk of developing type 2 diabetes.

28. (New): A nutraceutical composition for reducing the incidence or risk of type 2 diabetes in a human, the composition comprising a carrier, epigallocatechin gallate (EGCG), and phytanic acid.

29. (New): The composition according to any one of claims 25, 26, 27, or 28, wherein the composition further comprises pantethine.

30. (New): The composition according to any one of claims 27 or 28, wherein the human suffers from a condition selected from the group consisting of pre-diabetes, impaired glucose tolerance (IGT), obesity, and combinations thereof.

31. (New): The composition according to any one of claims 25, 26, 27, or 28, wherein the composition is a food, a beverage, a supplement for a food, or a supplement for a beverage.

32. (New): The composition according to any one of claims 25, 26, 27, or 28, wherein EGCG is present in an amount sufficient to administer to a subject a daily dosage of 0.3 mg per kg body weight to about 30 mg per kg body weight.

33. (New): The composition according to any one of claims 25, 26, 27, or 28, wherein phytanic acid is present in an amount sufficient to administer to a subject a daily dosage of 1 mg per kg body weight to about 100 mg per kg body weight.

34. (New): The composition according to claim 29, wherein pantethine is present in an amount sufficient to administer to a subject a daily dosage of 1 mg per kg body weight to about 50 mg per kg body weight.

35. (New): A unit dosage form for treating type 2 diabetes comprising a carrier, epigallocatechin gallate (EGCG) and phytanic acid.

36. (New): A unit dosage form for reducing the incidence or risk of diabetes type 2 in a human at risk of developing diabetes type 2 comprising a carrier, epigallocatechin gallate (EGCG), and phytanic acid.

37. (New): The unit dosage form according to any one of claims 35 or 36, wherein the composition further comprises pantethine.

38. (New): The unit dosage form according to claim 36, wherein the human suffers from a condition selected from the group consisting of pre-diabetes, impaired glucose tolerance (IGT), obesity, and combinations thereof.

39. (New): The unit dosage form according to claim 35 or 36 wherein the unit dosage form contains about 10 mg to about 500 mg of EGCG.

40. (New): The unit dosage form according to claim 35 or 36 wherein the unit dosage form contains about 30 mg to about 500 mg of phytanic acid.

41. (New): The composition according to claim 37 wherein the unit dosage form contains about 20 mg to about 1000 mg of pantethine.

42. (New): A composition for treating type 2 diabetes comprising epigallocatechin gallate (EGCG) and at least one additional active selected from the group consisting of pantethine, phytanic acid, and combinations thereof in admixture with a food or beverage.

43. (New): A composition for reducing the incidence or risk of type 2 diabetes in a human, the composition comprising epigallocatechin gallate (EGCG) and at least one additional active selected from the group consisting of pantethine, phytanic acid, and combinations thereof in admixture with a food or beverage.

44. (New): The composition according to claim 43, wherein the human suffers from a condition selected from the group consisting of pre-diabetes, impaired glucose tolerance (IGT), obesity, and combinations thereof.

45. (New): The composition according to any one of claims 42 or 43 comprising EGCG, pantethine or a metabolite thereof, phytanic acid, lipoic acid, policosanol and coenzyme Q-10.

46. (New): A method for treating diabetes in a human comprising administering to the human in need of such treatment a composition comprising epigallocatechin gallate (EGCG) and at least one additional active selected from the group consisting of pantethine, phytanic acid, and combinations thereof.

47. (New): A method for reducing the incidence or risk of diabetes type 2 in a human at risk of developing diabetes type 2 comprising administering to the human a composition comprising epigallocatechin gallate (EGCG) and at least one additional

active selected from the group consisting of pantethine, phytanic acid, and combinations thereof.

48. (New): The method according to claim 46, wherein the diabetes is type 1 diabetes.

50. (New): The method according to claim 47, wherein the diabetes is type 2 diabetes.

51. (New): The method according to any one of claims 46 or 47, wherein the composition comprises EGCG and pantethine.

52. (New): The method according to any one of claims 46 or 47, wherein the composition comprises EGCG and phytanic acid.

53. (New): The method according to any one of claims 46 or 47, wherein the composition comprises EGCG, pantethine, and phytanic acid.

54. (New): The method according to claim 47, wherein the human suffers from a condition selected from the group consisting of pre-diabetes, impaired glucose tolerance (IGT), obesity, and combinations thereof.

55. (New): The method according to claim 46 or 47, wherein the composition contains EGCG in an amount sufficient to provide a daily dosage of 0.3 mg per kg body weight to about 30 mg per kg body weight of the subject to which it is to be administered, pantethine, if present, in an amount sufficient to provide a daily dosage of 1.0 mg per kg body weight to about 50 mg per kg body weight of the subject to which it is to be administered, and phytanic acid, if present, in an amount sufficient to provide a daily dosage of 1.0 mg per kg body weight to about 100 mg per kg body weight of the subject to which it is to be administered.